Status:
UNKNOWN
Add-on Study on WHO Solidarity Trial Plus for COVID-19 in Nepal
Lead Sponsor:
Nepal Health Research Council
Collaborating Sponsors:
World Health Organization
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Proposal for Sub-Study to be conducted with the WHO Solidarity Plus Trial: Apart from the data been collected as per the WHO Solidarity Trial Plus protocol, Nepal Health Research Council will conduct...
Detailed Description
Patients enrolled in the WHO Solidarity Plus trial will also be consented for this sub-study for further data collection in the following four categories. No additional tests or investigations will be...
Eligibility Criteria
Inclusion
- Recently hospitalized (or already in hospital) with laboratory-confirmed COVID
- In the view of their doctors, no contra-indication to any potentially relevant study drug.
- Voluntary Participation
Exclusion
- In the view of the randomising doctor, ANY of the AVAILABLE study drugs are contra-indicated (eg, because of patient characteristics, chronic liver or heart disease, or some concurrent medication).
- If expected to be transferred within 72 hours
Key Trial Info
Start Date :
December 6 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT05273242
Start Date
December 6 2021
End Date
December 1 2022
Last Update
March 25 2022
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Chitwan Medical College
Bharatpur, Bagmati, Nepal
2
Civil Service Hospital
Kathmandu, Bagmati, Nepal
3
Patan Academy of Health Sciences
Lalitpur, Bagmati, Nepal
4
Lumbini Provincial Hospital
Butwāl, Lumbini, Nepal